Seeking adult men and women with HER2 positive breast cancer who have already received treatment to determine if a combination of different drugs is better than the usual treatment alone in preventing this cancer from returning.
This study seeks to determine if the combination of T-DM1 and a newer drug tucatinib is better than usual treatment with T-DM1 alone at preventing HER2 positive breast cancer from returning.
What we're hoping for
We want to find out if the approach of this study is better or worse than the usual approach most people get for their breast cancer.
ClinicalTrials.gov Identifier: NCT04457596